The complaint filed against ADMA Biologics alleges that the company engaged in undisclosed related-party transactions and utilized channel stuffing to artificially inflate reported revenue. Plaintiffs contend these practices, coupled with a failure to maintain robust internal controls, rendered the firm's public financial statements materially misleading throughout the specified period. When these details surfaced, the resulting market correction caused significant losses for shareholders.

Schall, Brown & Schwartz LLP is currently organizing the litigation on behalf of affected investors. While the class has not yet been certified, interested parties may contact partners Brian Schall or David Schwartz to discuss potential recovery options. Participation as a lead plaintiff is optional, and shareholders who choose not to act remain absent class members until the court grants certification.